RED BLOOD CELL ALLOIMMUNIZATION IN MULTI-TRANSFUSED PATIENTS

Amaal Mohamed Masoud;

Abstract


- This study was conducted to correlate the recurrent blood transfusion with the incidence of red blood cell alloimmunization .
- The study group included 200 patients examined for presence red blood cells alloantibodies .
- The majority of patients were previously transfused with blood matched only for ABO & D antigen .
- IN this study was noticed increase incidence of red blood cell alloimmunization in transfusion dependent patients where we noticed the rate of alloimmunization in multi transfused patient 28,5% which is high rate compared to the previous studies .
- IT was noticed the majority of red blood cells alloantibody formation was against Kell & RH blood group systems .
- WE found strong correlation between the number of blood units transfused and alloantibody formation .
- AND noticed that the gender was not a risk factor for alloimmunization .
- Alloantibodies can lead to serious clinical consequences so must be prevented & prevention of such serious events is possible by extended matching and typing of donor’s blood against the patient’s all the possible antigens, but this process is cumbersome and costly so identifying a high-risk group will be a feasible first target .
- Obtaining RBC antigenic phenotype on all multiple transfused patients, providing leukodepleted blood, matched for antigens of the ABO‐D and Kell systems in patients who have a life‐long transfusion dependency, could be so effective against red blood cell alloimmunization .


Other data

Title RED BLOOD CELL ALLOIMMUNIZATION IN MULTI-TRANSFUSED PATIENTS
Other Titles تكوين أجسام مضادة ضد كرات الدم الحمراء لمرضــى نقــل الــدم المتكــرر
Authors Amaal Mohamed Masoud
Issue Date 2014

Attached Files

File SizeFormat
g5917.pdf104.56 kBAdobe PDFView/Open
Recommend this item

Similar Items from Core Recommender Database

Google ScholarTM

Check

views 9 in Shams Scholar
downloads 13 in Shams Scholar


Items in Ain Shams Scholar are protected by copyright, with all rights reserved, unless otherwise indicated.